GHRP-2 + CJC-1295 No DAC Research Reference

Catalog classification, reference sizes, lab math links, and source-backed data. Educational use only — not medical advice.

Researched for: GHRP-2 and GHRH blend evidence

Growth Signal Blend blend Blend verified

Also known as: GHRP2/CJC

Quick Facts

Reference Sizes
10 mg total
Components
GHRP-2 + CJC-1295 No DAC
Calculator
Preset available
Storage
Use source-label storage wording. Track lot, storage location, and open/reconstitution date.
Solubility
No published mixed-formulation compatibility study exists

Blend Components

This entry is a multi-compound blend. Each component can be opened individually in the reconstitution calculator.

Component
GHRP-2
Calculator Profile
Component
CJC-1295 No DAC
Calculator Profile
Open All in Blend Calculator

Component amounts shown are arithmetic starters based on equal distribution. Edit values in the calculator before saving.

Catalog Description

GHRP-2 + CJC-1295 No DAC combines GHRP-2 + CJC-1295 No DAC into a single research protocol. Each component is independently studied; this entry summarizes the individual evidence base for the combination, since no unified safety/efficacy dataset covers the mixed formulation unless noted below. GHRP-2: Growth hormone-releasing hexapeptide analog (GHS-R1a agonist); balanced GH-release profile with measurable but modest cortisol/prolactin/ACTH co-stimulation vs. GHRP-6/hexarelin. CJC-1295 No DAC: CJC-1295 No DAC (Modified GRF 1-29) - short-acting GHRH analog; no albumin-binding moiety, half-life ~30 minutes; no published human trial data of its own. This is a community-stacking combination assembled from two independently studied compounds rather than a pharmaceutical sponsor's dedicated fixed-dose combination program - no dedicated human combination trial exists for this exact pairing as of this writing.

Catalog descriptions reflect research context only. Not a medical claim or treatment recommendation.

Research Profile

Half-Life
Component-specific; no fixed-blend pharmacokinetic study exists
Onset
Acute endocrine responses are expected within hours but are not characterized for the blend
Administration Routes (Research)
SC in gray-market useLaboratory use

Reported Research Effects

Reported Research Side Effects

Data source: Individual-component human studies and fixed-blend evidence-gap review

Reflects preclinical/research literature context only. Not a medical claim, dosing instruction, or treatment recommendation.

Research Protocols Reported in the Literature

Research Interactions

Flagged Avoid / Caution Combinations (Research)

Reflects patterns reported in research/community literature only. Not a safety guarantee, medical advice, or interaction warning for human use.

Research Notes

No-DAC CJC terminology is often used for modified GRF(1-29), whereas published CJC-1295 pharmacokinetic work concerns the DAC conjugate. Vendor naming must not be treated as proof of identity.

Supplementary research context only. Not medical advice or a treatment recommendation.

Sources

GHRP-2 pituitary response study — PubMed (NIH)
https://pubmed.ncbi.nlm.nih.gov/9285939/
CJC-1295 human pharmacokinetics — PubMed (NIH)
https://pubmed.ncbi.nlm.nih.gov/16352683/
GHRP review — PubMed (NIH)
https://pubmed.ncbi.nlm.nih.gov/16822960/

Suggest a community source

Found a relevant Reddit or forum thread about this compound? Suggest it below. Every suggestion is reviewed by an editor before it appears -- nothing is published automatically.

Related Research Articles

Published articles on this site that mention GHRP-2 + CJC-1295 No DAC or one of its catalog aliases.

Related Research Tools

Research Use Only. All content is for educational and research reference only. Not medical advice, a treatment recommendation, or guidance on human use. Compounds are not FDA-approved drugs unless specifically noted.

Scroll to Top